Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
O60383
UPID:
GDF9_HUMAN
Alternative names:
-
Alternative UPACC:
O60383; Q4VAW5
Background:
Growth/differentiation factor 9 (GDF9) plays a pivotal role in ovarian folliculogenesis, essential for primordial follicle development and granulosa cell proliferation. It facilitates cell cycle progression, enhancing CCND1 and CCNE1 expression, and RB1 phosphorylation. GDF9 also modulates STAR expression and progesterone release, counteracting activin A's effects by upregulating inhibin B, while suppressing FST and FSTL3 in granulosa-lutein cells.
Therapeutic significance:
GDF9's involvement in premature ovarian failure 14, due to gene variants, highlights its potential as a therapeutic target. Understanding GDF9's function could lead to innovative treatments for ovarian disorders, offering hope for affected individuals.